Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity

US10870692B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10870692-B2
Application numberUS-201916265437-A
CountryUS
Kind codeB2
Filing dateFeb 1, 2019
Priority dateAug 2, 2006
Publication dateDec 22, 2020
Grant dateDec 22, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.

First claim

Opening claim text (preview).

What is claimed is: 1. A purified multimer comprising a plurality of soluble, monoclonal antigen specific polypeptides, wherein each antigen specific polypeptide comprises a. a N-terminal leucine rich repeat (LRRNT), b. one or more internal leucine rich repeats (LRRs), c. a C-terminal leucine rich repeat (LRCCT), and d. a connecting peptide, wherein the connecting peptide comprises an alpha helix. 2. The multimer of claim 1 , comprising up to ten antigen specific polypeptides. 3. The multimer of claim 1 , wherein the antigen specific polypeptides bind a target protein. 4. The multimer of claim 1 , wherein the antigen specific polypeptides bind a target carbohydrate. 5. The multimer of claim 1 , wherein the antigen specific polypeptides bind a target pathogen. 6. The multimer of claim 2 , wherein the multimer is a multivalent multimer that binds to more than one target.

Assignees

Inventors

Classifications

  • Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site · CPC title

  • Orthomyxoviridae (F), e.g. influenza virus · CPC title

  • Bacillus (G) · CPC title

  • Specific host cells or culture conditions, e.g. components, pH or temperature · CPC title

  • for HIV · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10870692B2 cover?
Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptid…
Who is the assignee on this patent?
Uab Res Found
What technology area does this patent fall under?
Primary CPC classification C07K16/1278. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).